- Home
- VSCO vs SUPN Comparison
VSCO vs SUPN Comparison
Compare VSCO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- SUPN
- Stock Information
- Founded
- VSCO 1977
- SUPN 2005
- Country
- VSCO United States
- SUPN United States
- Employees
- VSCO N/A
- SUPN N/A
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- VSCO Consumer Discretionary
- SUPN Health Care
- Exchange
- VSCO Nasdaq
- SUPN Nasdaq
- Market Cap
- VSCO 1.9B
- SUPN 1.8B
- IPO Year
- VSCO N/A
- SUPN 2012
- Fundamental
- Price
- VSCO $19.43
- SUPN $33.18
- Analyst Decision
- VSCO Hold
- SUPN Hold
- Analyst Count
- VSCO 12
- SUPN 2
- Target Price
- VSCO $26.50
- SUPN $36.00
- AVG Volume (30 Days)
- VSCO 3.4M
- SUPN 760.7K
- Earning Date
- VSCO 08-27-2025
- SUPN 08-05-2025
- Dividend Yield
- VSCO N/A
- SUPN N/A
- EPS Growth
- VSCO 55.42
- SUPN N/A
- EPS
- VSCO 2.07
- SUPN 1.11
- Revenue
- VSCO $6,224,000,000.00
- SUPN $667,997,000.00
- Revenue This Year
- VSCO $2.23
- SUPN N/A
- Revenue Next Year
- VSCO $1.77
- SUPN $12.02
- P/E Ratio
- VSCO $9.24
- SUPN $29.92
- Revenue Growth
- VSCO 1.47
- SUPN 11.82
- 52 Week Low
- VSCO $13.76
- SUPN $27.05
- 52 Week High
- VSCO $48.73
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- VSCO 46.40
- SUPN 60.49
- Support Level
- VSCO $19.57
- SUPN $31.35
- Resistance Level
- VSCO $20.62
- SUPN $33.80
- Average True Range (ATR)
- VSCO 0.99
- SUPN 0.92
- MACD
- VSCO 0.11
- SUPN 0.16
- Stochastic Oscillator
- VSCO 39.44
- SUPN 79.12
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.